The study conducted by Florian L. et al. [204] clearly demonstrated a statistically significant or near-significant reduction in IL-23, TNF-α, and IL-17F, along with a notable decrease in the ESR, CRP, PASI, and DLQI scores, supporting the clinical and immunological efficacy of biologic treatments in moderate-to-severe psoriasis. The gene discussed is ESR1; the disease is psoriasis.